This announcement is not for release, publication or distribution in the United
States, Canada, Australia or Japan. This announcement is not an offer of
securities for sale in the United States or elsewhere.
TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
To the Copenhagen Stock Exchange
Announcement No. 21-07 / Copenhagen, 21 June 2007
Offering closed for applications for shares
As stated in TopoTarget A/S' offering circular of 4 June 2007, the subscription
period closed as of today at 16.00 CET and therefore the applications for
shares in the offering are now closed.
The result of the offering will be communicated in a stock exchange
announcement which is expected to be released at the latest 8:30 CET on Friday
22 June 2007.
TopoTarget A/S
For further information please contact:
Dr. Peter Buhl Jensen Phone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Background information
About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company,
headquartered in Denmark and with subsidiaries in the UK, Germany and the USA,
dedicated to finding ''Answers for Cancer'' and developing improved cancer
therapies. TopoTarget is founded and run by clinical cancer specialists and
combines years of hands-on clinical experience with in-depth understanding of
the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase
II inhibitors) and a strong devel-opment foundation has been built. TopoTarget
has a broad portfolio of small molecule preclinical
drug candidates and seven drugs are in clinical development, including both
novel anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™ is TopoTarget's first product on the market. In addition to organic
growth, TopoTarget consistently looks for opportunities to strengthen and
expand its activities through acquisitions and in-licensing. For more
information, please refer to www.topotarget.com.
